Home > Companies > United Laboratories, Inc.

United Laboratories, Inc.

unilab.com.ph

Driven by its genuine desire to make the lives of people better by providing quality products and services, Unilab is now the biggest pharmaceutical company in the Philippines, with a market share of some 20 percent which it has consistently maintained for more than three decades. Its portfolio includes some of the biggest prescription and consumer healthcare brands in the country.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

National Medtech & Biotech Summit 2024

Conference

Related News

Pharmacy Market

TAKEDA IS POISED TO COMMERCIALIZE NEXT GENERATION HUNTER'S DISEASE THERAPY THROUGH COLLABORATION WITH JCR PHARMACEUTICALS

Takeda Pharmaceutical Company Limited | October 01, 2021

Takeda Pharmaceutical Company Limited and JCR Pharmaceuticals Co., Ltd. today announce a geographically focused exclusive collaboration and license agreement to commercialize JR-141, a recombinant fusion protein under development of a next-generation antibody against the human transferrin receptor and the enzyme iduronate- 2-sulfatase (IDS), used to treat Hunter's disease (also called mucopolysaccharidosis type II or MPS II). Hunter's disease is caused by the lack of IDS and manifests it...

Business Insights

MERCK ENTERS COLLABORATION AND OPTION TO LICENSE AGREEMENT WITH NERVIANO MEDICAL SCIENCES TO DEVELOP NEXT-GENERATION PARP1 SELECTIVE INHIBITOR

Merck | September 22, 2022

Merck, a leading science and technology company, announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. for the next-generation highly selective and brain-penetrant PARP1 inhibitor, NMS-293. NMS-293 has strong potential in combination with a wide variety of DNA-damaging agents, including systemic or targeted chemotherapy or with DNA damage response inhibitors, in numerous tumor types. NMS-293 is in early clinical development for the treatment of patients ...

MERCK TO SPIN OFF WOMEN’S HEALTH AND BIOSIMILAR DRUG BUSINESSES

The Globe and Mail | February 05, 2020

Merck & Co Inc said on Wednesday it will spin off its women’s health, biosimilar drugs and older products into a separate publicly traded company as it tightens its focus on growth drivers like cancer drug Keytruda and vaccines. The new company’s assets currently make up around 15 per cent of Merck’s total sales and around half of its drugs that treat people. Merck will retain its animal health business, as well as drugs used for acute care in hospitals such as Bridion, whi...

Business Insights, PHARMA TECH

CONTINUUS PHARMACEUTICALS ADOPTS DIGITAL VALIDATION

CONTINUUS Pharmaceuticals | March 15, 2023

On March 14, 2023, ValGenesis, Inc., a leading enterprise validation lifecycle management solutions provider, announced that CONTINUUS Pharmaceuticals has successfully implemented the ValGenesis Validation Lifecycle Management System (VLMS) for efficient management of validation processes across the company in a 100% digital format. CONTINUUS Pharmaceuticals is a rapidly growing small business specializing in end-to-end integrated continuous manufacturing (ICM) of pharmaceutical...

Pharmacy Market